Synonym
Peliglitazar; BMS 426707-01; BMS-426707-1; BMS 42670701.
IUPAC/Chemical Name
Glycine, N-((4-methoxyphenoxy)carbonyl)-N-((1S)-1-(4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)ethyl)-
InChi Key
CUADMYMMZWFUCY-FQEVSTJZSA-N
InChi Code
InChI=1S/C30H30N2O7/c1-20(32(19-28(33)34)30(35)39-26-15-13-24(36-3)14-16-26)22-9-11-25(12-10-22)37-18-17-27-21(2)38-29(31-27)23-7-5-4-6-8-23/h4-16,20H,17-19H2,1-3H3,(H,33,34)/t20-/m0/s1
SMILES Code
O=C(O)CN(C(OC1=CC=C(OC)C=C1)=O)[C@H](C2=CC=C(OCCC3=C(C)OC(C4=CC=CC=C4)=N3)C=C2)C
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
530.58
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Wang L, Munsick C, Chen S, Bonacorsi S, Cheng PT, Humphreys WG, Zhang D. Metabolism and disposition of 14C-labeled peliglitazar in humans. Drug Metab Dispos. 2011 Feb;39(2):228-38. doi: 10.1124/dmd.110.035089. Epub 2010 Oct 26. PubMed PMID: 20978103.
2: Zhang D, Raghavan N, Wang L, Xue Y, Obermeier M, Chen S, Tao S, Zhang H, Cheng PT, Li W, Ramanathan R, Yang Z, Humphreys WG. Plasma stability-dependent circulation of acyl glucuronide metabolites in humans: how circulating metabolite profiles of muraglitazar and peliglitazar can lead to misleading risk assessment. Drug Metab Dispos. 2011 Jan;39(1):123-31. doi: 10.1124/dmd.110.035048. Epub 2010 Sep 28. PubMed PMID: 20876787.